Full Text View
Tabular View
No Study Results Posted
Related Studies
Phase II Study of Valproate and Doxorubicin in Malignant Mesothelioma
This study is ongoing, but not recruiting participants.
Study NCT00634205   Information provided by European Lung Cancer Working Party
First Received: March 5, 2008   Last Updated: April 3, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Malignant Mesothelioma
Additional conditions recognized in this trial
Mesothelioma
More general conditions related to this trial
Adenoma
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Mesothelial
Interventions listed in this trial
Valproate plus doxorubicin
Additional drug interventions recognized in this trial
Doxorubicin
Valproic Acid
More general drug interventions related to this trial
Antibiotics, Antineoplastic
Anticonvulsants
Antimanic Agents
Antineoplastic Agents
Central Nervous System Agents
Central Nervous System Depressants
Enzyme Inhibitors
GABA Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Therapeutic Uses
Tranquilizing Agents
Sponsors listed in this trial
European Lung Cancer Working Party


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services